If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

22 Dec 2017 11:30

RNS Number : 2392A
Concepta PLC
22 December 2017
 

22 December 2017

 

Concepta plc

 

("Concepta" or the "Company")

 

Trading update

 

Pursuant to the statement made on 6 November and 13 November 2017, Concepta plc, the UK healthcare company and developer of a proprietary platform and suite of products targeted at the mobile health market with a primary focus on women's fertility, provides shareholders today with an update on trading ahead of its 31 December 2017 year end.

 

Due to a labelling quality issue with the Company's manufacturer in China following its recent ramp up of production, the Company did not receive sufficient monitors to meet the order announced on 13 November. The majority of this order will now be delivered in January 2018. This issue, although now rectified, will have a distortion on the 2017 revenues which are now expected to be around £100,000. The Company will now recognise the majority of the revenue relating to this order in Q1 2018.

 

Orders have been increasing in the last few months of 2017 and with further new distributors likely to be appointed in the New Year the Board expects the delayed revenue referred to above to be additive to the 2018 budget. Following its recent fundraise, the Company has sufficient cash to meet its working capital requirements through 2018.

 

Erik Henau, CEO of Concepta plc said: "The team on the ground in China have been working hard over recent months to address issues identified within our supply chain as we continue to scale up production. The China team will have the support of David Darrock as Chief Operating Officer who has experience in the move from assembling products in a laboratory environment to full scale commercial manufacturing. We enforce strict quality control standards on our products and as such we have commenced a full supply chain evaluation with our suppliers and have implemented a number of measures to strengthen processes, for which we are already seeing significant improvements. Despite the impact of these issues I am confident that, following the improvements made, we are entering 2018 in a much stronger position."

 

ENDS

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Joint Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Novum Securities (Joint Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

 

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

 

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBBBDDCDDBGRD
Date   Source Headline
2nd Dec 20204:25 pmRNSChange of name to MyHealthChecked Plc
2nd Dec 202011:06 amRNSSecond Price Monitoring Extn
2nd Dec 202011:01 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20207:00 amRNSAcquisition of home-use genetic testing company
28th Sep 20207:00 amRNSHalf-year Report
22nd Jul 20207:00 amRNSChange of Adviser
6th Jul 20207:00 amRNSCommercial update; Change of registered office
2nd Jul 20203:24 pmRNSResult of AGM
5th Jun 20207:01 amRNSDirector/PDMR Shareholding
5th Jun 20207:00 amRNSNotice of Annual General Meeting
2nd Jun 20207:00 amRNSCommercial update
29th May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSPartnership agreement with Abingdon Health
27th Apr 20208:16 amRNSDirector/PDMR Shareholding
24th Apr 202011:26 amRNSResult of GM & Completion of Fundraise
14th Apr 20209:27 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSManufacturing outsourcing agreements for myLotus®
8th Apr 20207:00 amRNSPlacing and Subscription to raise £1.9 million
29th Jan 20207:00 amRNSTrading Update
14th Nov 20197:00 amRNSBoard Appointments
13th Nov 20198:35 amRNSBoard changes - replacement
13th Nov 20197:00 amRNSBoard Changes
31st Oct 20197:00 amRNSConcepta announces first myLotus® UK birth
25th Oct 20197:00 amRNSBoard Changes
30th Sep 20197:00 amRNSInterim Results
30th Sep 20197:00 amRNSFirst myLotus® UK Fertility Clinic collaboration
29th Jul 20197:00 amRNSGrant of Options
9th Jul 20197:00 amRNSmyLotus® pregnancies in double figures
13th Jun 20192:01 pmRNSResult of AGM
21st May 20199:00 amRNSNotice of AGM
14th May 20197:01 amRNSAnnual Results
14th May 20197:00 amRNSConcepta announces first myLotus® pregnancies
30th Apr 20194:28 pmRNSHolding(s) in Company
30th Apr 20191:46 pmRNSTR-1: form for notification of major holdings
29th Apr 20191:20 pmRNSTR-1: notification of major holdings
26th Apr 201910:52 amRNSDirector/PDMR Shareholding
8th Apr 20197:00 amRNSPlacing to raise £2.3m; Notice of General Meeting
29th Mar 20197:00 amRNSConcepta to supply myLotus® to Boots UK
12th Mar 20197:00 amRNSConcepta to supply myLotus® to Walgreens Boots
17th Dec 20187:00 amRNSmyLotus® successful UK launch
31st Oct 20187:00 amRNSmyLotus® launch at The Fertility Show, London
29th Oct 20187:00 amRNSmyLotus gains CE-mark regulatory approval
5th Oct 20182:42 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSGrant of Options
27th Sep 20184:41 pmRNSSecond Price Monitoring Extn
27th Sep 20184:37 pmRNSPrice Monitoring Extension
27th Sep 20187:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.